Skip to main content
SpringerLink
Log in

Ziprasidone, Zuclopenthixole, and Fluspirilene in the Treatment of Psychosis

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 57 Accesses

Abstract

Psychosis is the hallmark feature of psychotic spectrum disorders, such as schizophrenia, schizoaffective disorder, schizotypal personality, brief psychotic disorder, psychosis related with substance abuse, as well as developmental and degenerative medical conditions. The high rate of disability as a result of the psychological, social, and functional impairment imposes an early and specific intervention to reduce psychotic symptoms. The interindividual variability of psychotic episodes experienced by patients depends on the origin of the psychosis. Therefore, the management of psychosis involves a combination of both pharmacological and psychological interventions. Antipsychotics are the gold-standard treatment for psychosis. Since the development of antipsychotics depot injections in the 1960s (e.g., fluspirilene and zuclopenthixole) and second-generation antipsychotics (atypical antipsychotics) in the 1980s (e.g., ziprasidone), the response to treatment has improved substantially, minimizing relapses and the duration of untreated psychosis (DUP). The clinical use of ziprasidone and zuclopenthixole is widely extended, contrary to the use of fluspirilene that is limited due to the pharmacokinetics and adverse events of this long-acting injectable neuroleptic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Abhijnhan A, Adams CE, David A, Ozbilen M. Depot fluspirilene for schizophrenia. Cochrane Database Syst Rev. 2007;2007:CD001718.

    PubMed Central  Google Scholar 

  • Agid O, Kapur S, Warrington L, Loebel A, Siu C. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res. 2008;102:241–8.

    Article  Google Scholar 

  • Amdisen A, Nielsen MS, Dencker SJ, Fensbo C, Ahlfors UG, Gravem A, Baastrup PC, Bjerkenstedt L, Gunby B, Wiesel F-A, Lindholm H, Rafaelsen OJ, Fredslund-Andersen K, Thomsen NJ, Rosell I, Pakarinen P, Harma P, Amthor KF, Kastberg S, Abelskov J. Zuclopenthixol acetate in Viscoleo® – a new drug formulation: an open Nordic multicentre study of zuclopenthixol acetate in Viscoleo® in patients with acute psychoses including mania and exacerbation of chronic psychoses. Acta Psychiatr Scand. 1987;75:99–107.

    Article  CAS  Google Scholar 

  • Arciniegas DB. Psychosis. Contin Lifelong Learn Neurol. 2015;21:715–36.

    Article  Google Scholar 

  • Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Eigen K, Brekke B, Fredslund-Andersen K, Lindholm H, Lybeck I, Morawski R, Nummi K, Silfverhjelm H, Vartiainen H, Wiesel FA, Aarvold A. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatr Scand. 1993;87:48–58.

    Article  CAS  Google Scholar 

  • Bankier RG. A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis. J Clin Pharmacol New Drugs. 1973;13:44–7.

    Article  CAS  Google Scholar 

  • Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115:97–103.

    Article  Google Scholar 

  • Bürgy M. The concept of psychosis: historical and phenomenological aspects. Schizophr Bull. 2008;34:1200–10.

    Article  Google Scholar 

  • Chokhawala K, Stevens L. Antipsychotic medications. Treasure Island: StatPearls Publishing; 2020.

    Google Scholar 

  • Clopixol 200 mg/ml solution for injection – Summary of Product Characteristics (SmPC) – (eMC) [WWW Document] (2016) Electron. Med. Conpendium. URL https://www.medicines.org.uk/emc/product/6414#PHARMACOKINETIC_PROPS. Accessed 16 Nov 2020

  • Crespo-Facorro B, Ortiz-García de la Foz V, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Vázquez-Barquero JL, Pérez-Iglesias R. Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial. Schizophr Res. 2013a;147:375–82.

    Article  Google Scholar 

  • Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ortiz-Garcia De La Foz V, Martínez-Garcia O, Valdizan EM, Vazquez-Barquero JL. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison. J Clin Psychopharmacol. 2013b;33:215–20.

    Article  CAS  Google Scholar 

  • Crespo-Facorro B, Ortiz-Garcia De La Foz V, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O, Pérez-Iglesias R. Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology. 2014;231:357–66.

    Article  CAS  Google Scholar 

  • Daniel D, Zimbroff D, Potkin S, Reeves K, Harrigan E, Lakshminarayanan M, Group, Z.S. Ziprasidone 80 mg / day and 160 mg / day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week. Neuropsychopharmacology. 1999;20:491–505.

    Article  CAS  Google Scholar 

  • Dunayevich E, Keck PE. Prevalence and description of psychotic features in bipolar mania. Curr Psychiatry Rep. 2000;2:286–90.

    Article  CAS  Google Scholar 

  • Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Ortiz-García de la Foz V, Vázquez-Bourgon J, González-Pinto A, Crespo-Facorro B. Long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol. 2018;21:1090–101.

    Article  Google Scholar 

  • Gravem A, Bugge A. Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. Acta Psychiatr Scand. 1981;64:13–9.

    Google Scholar 

  • Gründer G, Heinze M, Cordes J, Mühlbauer B, Juckel G, Schulz C, Rüther E, Timm J. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016;3:717–29.

    Article  Google Scholar 

  • Heikkilä L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. Curr Med Res Opin. 1992;12:594–603.

    Article  Google Scholar 

  • Hovens JE, Dries PJT, Melman CTM, Wapenaar RJC, Loonen AJM. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol. 2005;19:51–7.

    Article  CAS  Google Scholar 

  • Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51.

    Article  CAS  Google Scholar 

  • Jafari S, Fernandez-Enright F, Huang XF. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. J Neurochem. 2012;120:371–84.

    Article  CAS  Google Scholar 

  • Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry. 2010;10:1.

    Article  Google Scholar 

  • Johnsen E, Sinkeviciute I, Løberg EM, Kroken RA, Hugdahl K, Jørgensen HA. Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. BMC Psychiatry. 2013;13:1–10.

    Article  Google Scholar 

  • Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res. 2010;44:8–14.

    Article  Google Scholar 

  • Leonard BE. The pharmacology of the phenothiazines, butyrophenones, thioxanthines and diphenylbutylpiperidines. In: Antipsychotic drugs and their side-effects. London: Academic; 1993. p. 3–26.

    Chapter  Google Scholar 

  • Li YM, Zhao JP, Ou JJ, Wu RR. Efficacy and tolerability of ziprasidone vsolanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study. Pharmacopsychiatry. 2012;45:177–81.

    CAS  PubMed  Google Scholar 

  • Lowert AC, Rasmussen EM, Holm R, Almbjerg F, Calberg H, Joensen A, Nimb M, Baden H, Andersen E, Westergard T, Larsen H, Magelund C. Acute psychotic disorders treated with 5% zuclopenthixol acetate in “Viscoleo” (‘Cisordinol-Acutard’), a global assessment of the clinical effect: an open multi-centre study. Pharmatherapeutica. 1989;5:380–6.

    CAS  PubMed  Google Scholar 

  • Manea M, Rusanu V, Patrichi BE, Puiu MG, Stoean RM, Stefanache AA. Olanzapine and zuclopenthixol combined therapy for the treatment of refractory schizophrenia: 2 case reports. Eur Psychiatry. 2011;26:1437.

    Article  Google Scholar 

  • Matar AM, Abdel-Mawgoud M, Skov S. Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial. J Clin Psychopharmacol. 1990;10:283–6.

    Article  CAS  Google Scholar 

  • Miceli J, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull. 2007;40:58–68.

    PubMed  Google Scholar 

  • Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017;6:1–199.

    Google Scholar 

  • Pijnenborg GHM, Timmerman ME, Derks EM, Fleischhacker WW, Kahn RS, Aleman A. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: data from the European First-Episode Schizophrenia Trial (EUFEST). Eur Neuropsychopharmacol. 2015;25:808–16.

    Article  CAS  Google Scholar 

  • Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35:61–6.

    Article  CAS  Google Scholar 

  • Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phiphopthatsanee N, Amir T, Yenn Thoo H, Oliver D, Davies C, Morgan C, McGuire P, Murray RM, Fusar-Poli P. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry. 2018;17:49–66.

    Article  Google Scholar 

  • Rubio G, Martínez I, Ponce G, Angel Jiménez-Arriero M, López-Muñoz F, Álamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatr. 2006;51:531–9.

    Article  Google Scholar 

  • San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Res. 2012;200:693–701.

    Article  CAS  Google Scholar 

  • Shaw V, Srivastava S, Srivastava SK. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy [published online ahead of print, 2019 Oct 13]. Semin Cancer Biol. 2019;S1044-579X(19)30144-0. https://doi.org/10.1016/j.semcancer.2019.10.007.

  • Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung H, Lu D, Wong MH, Lin MCM. In silico identification and in vitro and in vivo validation of anti-psychotic drug fluspirilene as a potential CDK2 inhibitor and a candidate anti-cancer drug. PLoS One. 2015;10:1–22.

    Google Scholar 

  • Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54:55–9.

    Article  Google Scholar 

  • Wang HH, Cai M, Wang HN, Chen YC, Zhang RG, Wang Y, McAlonan GM, Bai YH, Wu WJ, Guo L, Zhang YH, Tan QR, Zhang ZJ. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders. J Psychiatr Res. 2017;85:59–65.

    Article  Google Scholar 

  • Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Translational Neuroscience Research Group, Galicia Sur Health Research Institute (IISGS), CIBERSAM, Vigo, Spain

    Daniela Rodrigues-Amorim

  2. Department of Psychiatry, Hospital Álvaro Cunqueiro, Vigo, Spain

    José Manuel Olivares

  3. Research Area of Translational Neuroscience, Galicia Sur Health Research Institute (IISGS), CIBERSAM, Vigo, Spain

    José Manuel Olivares

Authors
  1. Daniela Rodrigues-Amorim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Manuel Olivares
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Manuel Olivares .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Bayern, Germany

    Christian Riederer

Section Editor information

  1. Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany

    Frank Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Rodrigues-Amorim, D., Olivares, J.M. (2021). Ziprasidone, Zuclopenthixole, and Fluspirilene in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_415-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_415-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation